{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Subjects will be discharged from the study center after all of the procedures have been', 'completed.', 'The end of the trial is defined as the last visit date of the last subject undergoing the trial.', '9.5.6.14.2', 'Month 12 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-301', 'Subjects who complete the Week 24 Visit will be contacted 6 months later via phone', 'or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', '9.5.6.15', 'Month 18', '9.5.6.15.1', 'Month 18 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', 'Subjects who complete the Month 12 Visit will be contacted 6 months later via phone or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', '9.5.6.15.2', 'Month 18 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-301', 'Subjects who complete the Week 24 Visit will be contacted 12 months later via phone', 'or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'This is the final contact for subjects who relapsed in Study HZNP-TEP-301.', '9.5.6.16', 'Month 24 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', 'Subjects who complete the Month 12 Visit will be contacted 12 months later via phone or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 27 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'This is the final contact for proptosis non-responders in Study HZNP-TEP-301.', 'The end of the trial is defined as the date of the last subject contact at Month 24.', '9.6.1', 'Enppoints', 'Study endpoints will be evaluated for all subjects from Baseline to Week 24 the EOT Visit.', '9.6.1.1 Primary Endpoint', 'The primary outcome measure is the proptosis responder rate (percentage of subjects with a', '>2 mm reduction from Baseline in proptosis in the study eye, without deterioration 1> 2 mm', 'increase] of proptosis in the fellow eye) at Week 24the EOT Visit.', '9.6.1.2 Secondary Enppoints', '1.', 'Percentage of subjects with a CAS value of 0 or 1 in the study eye at Week 24the EOT', 'Visit.', '2.', 'Mean change from Baseline to Week 24 EOT in proptosis measurement in the study', 'eye.', '3.', 'Diplopia responder rate (percentage of subjects with baseline diplopia > 0 in study', 'eye who have a reduction of > 1 grade with no corresponding deterioration', '1 grade worsening in the fellow eye) at Week 24.', '4.3. Mean change from Baseline to Week 24 EOT in the GO-QoL questionnaire overall', 'score.', '9.6.1.3', 'Exploratory Enppoints', '1. The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND', '> 2 mm reduction in proptosis from Baseline, provided there is no corresponding', 'deterioration [ 2 point/mm increase] in CAS or proptosis in the fellow eye) at Week 24', 'the EOT Visit.', '2. The Clinical Measures of Severity individual response status frequencies and percentage', 'of responders for each component of clinical severity at Week 24 EOT.', '3. The mean change from Baseline to Week 24 EOT in the CAS.', '4. The overall responder rate at Week 24 EOT-stratified by the level of response (high', 'responders, responders, low responders, and non-responders; see Section 9.6.3.2.1 for', 'definitions).', '5. The mean change from Baseline to Week 24 EOT in the GO-QoL questionnaire VF and', 'A subscale scores.', '6. The mean change from Baseline to Week 24 EOT on the motility component of the', 'Clinical Measures of Severity.', '7. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure', 'and understand PK-PD relationships.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 28 of 118']\n\n###\n\n", "completion": "END"}